Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3
October 25, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK
September 16, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
September 15, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to participate in upcoming virtual investor conferences
September 02, 2021 07:00 ET
|
Autolus Therapeutics plc
- Goldman Sachs Eleventh Annual Biotech Symposium on September 7- 2021 Virtual Wells Fargo Healthcare Conference on September 10 at 7.30am ET - H.C. Wainwright & Co 23rd Annual Global Investment...
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology
September 01, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
August 09, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress
August 05, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus
August 02, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer
July 15, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021
July 08, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...